Time:
All Today Tomorrow This Week This Month

Rapid assembly of gene variant libraries to engineer proteins for user defined goals

Mutant libraries can be used to optimize protein function, such as enhancing expression levels, protein stability and activity, antibody affinity maturation and removal of hot spot degradation.

06-30-2019 Charlie Zou, Ph.D. Project Manager, GenScript

Learn More

Expression of Toxic Genes in E. coli: Special Strategies and Genetic Tools

Escherichia coli is the most efficient and widely-used host for synthetic biology, metabolic engineering, protein production and plasmid replication.

06-30-2019 Dr. Fanglong Zhao is a senior scientist at GenScript USA Inc.

Learn More

Amplified Extracellular Vesicles Generation Triggered by Peptide Polymerization

This webinar introduces a novel invention using intercellular polymerization of a synthetic peptide precursor to amplify the generation of extracellular vesicles (EVs).

05-01-2019 Hiroshi Matsui, Ph.D., Professor at City University of New York

Learn More

Characterizing B cells and Their Antibodies Using Single-Cell RNA Sequencing (scRNA-seq)

The study of single cells has provided insights into the composition and function of an increasing number of biological systems across both health and disease. Single-cell RNA sequencing (scRNA-seq) is a particularly powerful approach that can provide the

04-24-2019 Derek Croote, Researcher at Stanford University

Learn More

Tips to Generate & Troubleshoot ELISA Experiments for Your Application

The Enzyme-Linked Immunosorbent assay (ELISA) is one of the most commonly used analytical biochemical assays in both academic laboratories and pharmaceutical companies alike.

04-17-2019 Hui Chen, Ph.D., Director, Antibody Department, GenScript

Learn More

Identification of Relevant Antigenic Targets for Successful Liver Cancer Immunotherapy

HCC is a major cause of cancer-related death in the world and the current available treatments are effective only at an early stage. For advanced HCC the only approved therapy is Sorafenib (a multi kinase inhibitor) which has low response rate (about 3%).

04-10-2019 Anna Pasetto, Ph.D. Assistant Professor, Karolinska Institutet

Learn More

< 20 21 22 23 24 25 26 27 28 29 30 > Total Pages 36